Berlin, Germany – June 17, 2025 – Captain T Cell, a biotech firm focused on developing advanced TCR-based cell therapies for solid tumor patients, has been selected to join the Bayer Co.Lab incubator in Berlin.
The Bayer Co.Lab program fosters innovation in biotech and life sciences by providing access to advanced lab and office facilities, global expertise, and Bayer’s extensive life science network. Situated at Bayer’s Pharmaceuticals Division headquarters, Bayer Co.Lab Berlin serves as a key hub within the company’s global incubator network, designed to accelerate the development of groundbreaking technologies for patient use.
“We are honored to be a part of Bayer Co.Lab and to be acknowledged as a leading innovator in the TCR-T field,” stated Dr. Felix Lorenz, CEO of Captain T Cell. “As we advance our primary program towards clinical trials, our proximity to Bayer’s pharma hub will enhance our clinical and translational strategy and enable us to create impactful TCR programs. We are enthusiastic about growing within this environment and continuing to advance the field of solid tumor therapy.”
Captain T Cell is developing a proprietary TCR-T cell therapy platform encompassing both autologous and allogeneic candidates. Its lead autologous program, CTC 127, has shown exceptional in vivo effectiveness in preclinical studies, with human clinical trials planned to begin in 2027. The company’s novel allogeneic platform has recently demonstrated promising preclinical in vivo results, a significant achievement for off-the-shelf cell therapies.
“Bayer Co.Lab is dedicated to supporting visionary teams addressing the most challenging scientific problems,” said Dr. Ruth Shah, Head of Bayer Co.Lab Berlin. “We are thrilled to welcome Captain T Cell to our expanding community of select scientific innovators and are eager to support their mission to revolutionize solid tumor treatment through next-generation cell therapies.”
Captain T Cell recently received first place for “Biggest Scientific Breakthrough” at the Grand Opening of Bayer Co.Lab Berlin. The company joins a growing group of promising life science ventures in one of Europe’s most vibrant innovation centers for oncology and advanced therapeutics.
###
About Captain T Cell
Captain T Cell GmbH is a biotech company creating next-generation TCR-based cell therapies for solid tumors. Utilizing a strong TCR discovery and toolbox platform, the company is advancing both autologous and allogeneic TCR-T products, aiming to provide effective treatment options for patients with difficult-to-treat cancers. For more information, visit .
About Bayer Co.Lab
Bayer Co.Lab is a leading global network of life science incubators focused on transformative innovation and scientific discoveries. With strategic locations worldwide, including Berlin, Germany; Cambridge, USA; Kobe, Japan; and Shanghai, China, Bayer Co.Lab connects early-stage entrepreneurs with world-class knowledge, resources, and global networks – without any obligations. Bayer Co.Lab empowers forward-thinking startups by providing state-of-the-art facilities, expert guidance, and a dynamic community where they can transform innovative ideas into impactful healthcare solutions. To discover more, visit .
Media Contacts:
Dr. Janna Hachmann
Captain T Cell GmbH
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
“`
